Cellectis S.A. American Depositary Shares (CLLS) Stock Price

CLLSStock

$1.04−66.73%52W

Market Cap$104.76M

P/E—

PEG Ratio—

Div yield—

Beta1.13

CLLS Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-82.59%

Price vs S&P 500 (4W)-20.65%

VGM Score47.12

P/CF (Annual)10.79x

Book Value / Share (Quarterly)$0.56

P/TBV (Annual)4.47x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)45.72%

Cash Flow / Share (Quarterly)$-0.62

Price vs S&P 500 (YTD)-85.93%

Gross Margin (TTM)34.83%

Net Profit Margin (TTM)-76.00%

EPS (TTM)$-0.82

10-Day Avg Trading Volume0.24M

EPS Excl Extra (TTM)$-0.82

Revenue Growth (5Y)5.97%

EPS (Annual)$-0.67

ROI (Annual)-36.47%

Gross Margin (Annual)43.61%

Net Profit Margin (5Y Avg)-393.48%

Cash / Share (Quarterly)$2.30

Revenue Growth QoQ (YoY)-52.18%

ROA (Last FY)-20.82%

Revenue Growth TTM (YoY)16.06%

EBITD / Share (TTM)$-0.59

ROE (5Y Avg)-75.60%

Operating Margin (TTM)-69.22%

Cash Flow / Share (Annual)$-0.59

P/B Ratio2.06x

P/B Ratio (Quarterly)5.10x

Net Income / Employee (Annual)$-295,200

EV / Revenue (TTM)1.34x

Net Interest Coverage (TTM)-0.95x

ROA (TTM)-26.95%

EPS Incl Extra (Annual)$-0.67

Current Ratio (Annual)1.62x

Quick Ratio (Quarterly)1.34x

3-Month Avg Trading Volume0.28M

52-Week Price Return-66.73%

EV / Free Cash Flow (Annual)8.19x

Revenue / Employee (TTM)$473,900

Tangible BV / Share (Quarterly)$0.55

P/S Ratio (Annual)1.07x

Asset Turnover (Annual)0.25x

52-Week High$4.75

Operating Margin (5Y Avg)-367.53%

EPS Excl Extra (Annual)$-0.67

CapEx CAGR (5Y)-41.81%

Tangible BV CAGR (5Y)-22.75%

26-Week Price Return-72.69%

Quick Ratio (Annual)1.61x

13-Week Price Return-55.01%

Total Debt / Equity (Annual)1.44x

Current Ratio (Quarterly)1.37x

Enterprise Value$145.97M

Revenue / Share Growth (5Y)-10.75%

Asset Turnover (TTM)0.35x

Book Value / Share Growth (5Y)-30.44%

Revenue / Employee (Annual)$347,600

Inventory Turnover (Annual)82.27x

Pretax Margin (Annual)-85.46%

Cash / Share (Annual)$2.88

3-Month Return Std Dev108.46%

Gross Margin (5Y Avg)-84.99%

Net Income / Employee (TTM)$-360,200

ROE (Last FY)-89.05%

Net Interest Coverage (Annual)-0.85x

EPS Basic Excl Extra (Annual)$-0.67

P/FCF (TTM)1.72x

Receivables Turnover (TTM)15.67x

Total Debt / Equity (Quarterly)2.36x

EPS Incl Extra (TTM)$-0.82

Receivables Turnover (Annual)7.54x

ROI (TTM)-48.22%

P/S Ratio (TTM)0.78x

Pretax Margin (5Y Avg)-412.20%

Revenue / Share (Annual)$0.79

Tangible BV / Share (Annual)$1.04

Price vs S&P 500 (52W)-82.26%

Year-to-Date Return-75.38%

5-Day Price Return-9.31%

EPS Normalized (Annual)$-0.67

ROA (5Y Avg)-26.23%

Net Profit Margin (Annual)-84.92%

Month-to-Date Return-22.62%

Cash Flow / Share (TTM)$-0.66

EBITD / Share (Annual)$-0.13

Operating Margin (Annual)-41.56%

LT Debt / Equity (Annual)0.98x

ROI (5Y Avg)-39.44%

LT Debt / Equity (Quarterly)1.61x

EPS Basic Excl Extra (TTM)$-0.82

P/TBV (Quarterly)5.24x

P/B Ratio (Annual)4.44x

Inventory Turnover (TTM)93.83x

Pretax Margin (TTM)-76.28%

Book Value / Share (Annual)$1.05

Price vs S&P 500 (13W)-57.69%

Beta1.13x

P/FCF (Annual)4.43x

Revenue / Share (TTM)$1.08

ROE (TTM)-118.96%

52-Week Low$1.02

vGradeB

gGradeC

mGradeD

vgmGradeC

CLLS Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 6, 2026	-$0.26	-$0.22	+16.35%(+$0.04)
Q1 2026	May 11, 2026	-$0.26	-$0.18	+30.77%(+$0.08)
Q4 2025	Mar 19, 2026	-$0.10	-$0.24	-140.00%(-$0.14)
Q3 2025	Nov 7, 2025	-$0.10	$0.02	+120.00%(+$0.12)
Q2 2025	Aug 4, 2025	-$0.15	-$0.22	-46.67%(-$0.07)

CLLS Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

4.23

Industry Peers — Biological Products(186)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
CLLSCellectis S.A. American Depositary Shares	B	C	D	0.8x	16.1%	34.8%	—	$1.04
AMGNAmgen Inc	D	C	A	6.1x	9.1%	74.3%	2.9%	$432.49
GILDGilead Sciences Inc	C	B	A	6.4x	5.5%	79.6%	133.6%	$156.19
MRNAModerna, Inc. Common Stock	F	C	A	39.1x	-27.6%	36.4%	—	$218.01
ARGXargenx SE American Depositary Shares	D	A	B	6.6x	165.2%	89.8%	—	$819.14
RVMDRevolution Medicines, Inc. Common Stock	F	—	B	3296.2x	—	—	—	$177.96
BIIBBiogen Inc. Common Stock	C	D	A	3.4x	0.3%	74.0%	-18.8%	$232.65
BNTXBioNTech SE American Depositary Share	C	C	C	7.6x	-11.8%	79.2%	—	$87.71
EXELExelixis Inc	C	B	A	6.3x	9.2%	96.5%	31.1%	$62.23
HALOHalozyme Therapeutics, Inc.	D	B	A	8.3x	41.1%	82.4%	22.9%	$121.84
NBIXNeurocrine Biosciences Inc	C	B	B	4.1x	34.4%	98.0%	2.3%	$135.71
TECHBio-Techne Corp.	D	C	B	9.4x	-0.4%	66.2%	6.0%	$72.57
RGENRepligen Corp	F	C	A	14.2x	16.5%	53.8%	-4.9%	$175.42
APGEApogee Therapeutics, Inc. Common Stock	—	—	A	—	—	—	—	$135.07
PCVXVaxcyte, Inc. Common Stock	—	—	B	—	—	—	—	$63.62
IBRXImmunityBio, Inc. Common Stock	F	A	A	58.7x	192.9%	99.3%	—	$9.18
QGENQIAGEN N.V.	C	C	B	4.5x	3.0%	62.5%	4.2%	$46.13
KRYSKrystal Biotech, Inc. Common Stock	D	B	B	21.3x	22.6%	94.6%	—	$316.58
TWSTTwist Bioscience Corporation Common Stock	D	B	A	20.2x	19.2%	52.0%	—	$132.75
KYMRKymera Therapeutics, Inc. Common Stock	F	B	B	83.0x	134.8%	—	—	$104.78
IOVAIovance Biotherapeutics, Inc. Common Stock	D	B	A	19.0x	34.5%	48.4%	—	$13.62
IMVTImmunovant, Inc. Common Stock	—	—	C	—	—	—	—	$26.73
KODKodiak Sciences Inc Common Stock	—	—	A	—	—	—	—	$85.75
CGONCG Oncology, Inc. Common stock	F	A	B	851.8x	1030.3%	-85.2%	—	$59.85
SRRKScholar Rock Holding Corporation Common Stock	F	—	C	102.7x	—	—	—	$39.90
CRSPCRISPR Therapeutics AG	D	B	B	355.6x	-64.8%	—	—	$49.25
ADPTAdaptive Biotechnologies Corporation Common Stock	D	B	B	12.4x	50.1%	75.6%	—	$24.02
RLAYRelay Therapeutics, Inc. Common Stock	F	D	B	344.7x	23.9%	—	—	$16.28
TARSTarsus Pharmaceuticals, Inc. Common Stock	D	A	B	5.5x	105.2%	93.3%	—	$68.07
DNLIDenali Therapeutics Inc. Common Stock	F	—	C	781.1x	—	—	—	$17.61
BEAMBeam Therapeutics Inc. Common Stock	D	B	C	15.5x	158.9%	—	—	$23.47
ADMAADMA Biologics, Inc.	C	C	B	4.7x	8.0%	64.7%	—	$10.68
VCELVericel Corporation	D	B	B	6.7x	22.9%	74.6%	38.9%	$40.13
BCRXBioCryst Pharmaceuticals Inc	B	A	B	2.1x	68.7%	97.8%	—	$7.79
RXRXRecursion Pharmaceuticals, Inc. Class A Common Stock	D	C	C	33.9x	-15.1%	3.5%	—	$3.46
NVAXNovavax Inc	C	D	B	4.5x	-61.6%	79.2%	—	$11.26
ALVOAlvotech Ordinary Shares	D	D	B	3.9x	-12.1%	60.7%	—	$5.00
MESOMesoblast Limited American Depositary Shares	D	A	C	14.6x	599.2%	86.1%	—	$13.28
VIRVir Biotechnology, Inc. Common Stock	B	B	B	5.6x	1496.1%	100.0%	—	$9.96
MAZEMaze Therapeutics, Inc. Common Stock	—	A	B	—	700.0%	—	—	$27.53
IMCRImmunocore Holdings plc American Depositary Shares	D	B	B	3.5x	20.9%	98.9%	—	$29.40
COAGHemab Therapeutics Holdings, Inc. Common Stock	—	—	C	—	—	—	—	$30.07
INBXInhibrx Biosciences, Inc. Common Stock	D	C	A	944.3x	550.0%	—	—	$89.83
TSHATaysha Gene Therapies, Inc. Common Stock	D	C	D	120.7x	-32.3%	—	—	$3.62
IMTXImmatics N.V. Ordinary Shares	C	C	C	21.5x	-68.0%	—	—	$6.73
REPLReplimune Group, Inc.	—	—	B	—	—	—	—	$10.86
VORVor Biopharma Inc. Common Stock	—	—	C	—	—	—	—	$18.03
MGTXMeiraGTx Holdings plc Ordinary Shares	C	A	C	2.2x	948.4%	98.0%	—	$9.28
SLBTSL Science Holding Limited Ordinary Shares	—	—	D	—	—	—	—	$1.53
CGEMCullinan Therapeutics, Inc. Common Stock	—	—	C	—	—	—	—	$12.93
GLUEMonte Rosa Therapeutics, Inc. Common Stock	D	F	D	28.9x	-83.9%	—	—	$9.74

About Cellectis S.A. American Depositary Shares

Cellectis SA is a clinical-stage biotechnology company developing gene-editing treatments for cancer and other diseases. The company's pipeline includes allogeneic CAR-T cell therapies for immuno-oncology and gene-edited stem cell products for other therapeutic areas. Its proprietary technology platform creates off-the-shelf cellular therapies with the potential for improved clinical outcomes and broader patient access.